These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 24722153)
1. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. Wynes MW; Sholl LM; Dietel M; Schuuring E; Tsao MS; Yatabe Y; Tubbs RR; Hirsch FR J Thorac Oncol; 2014 May; 9(5):631-8. PubMed ID: 24722153 [TBL] [Abstract][Full Text] [Related]
2. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. Thorne-Nuzzo T; Williams C; Catallini A; Clements J; Singh S; Amberson J; Dickinson K; Gatalica Z; Ho SN; Loftin I; McElhinny A; Towne P J Thorac Oncol; 2017 May; 12(5):804-813. PubMed ID: 28147239 [TBL] [Abstract][Full Text] [Related]
3. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm. Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275 [TBL] [Abstract][Full Text] [Related]
6. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. Conde E; Suárez-Gauthier A; Benito A; Garrido P; García-Campelo R; Biscuola M; Paz-Ares L; Hardisson D; de Castro J; Camacho MC; Rodriguez-Abreu D; Abdulkader I; Ramirez J; Reguart N; Salido M; Pijuán L; Arriola E; Sanz J; Folgueras V; Villanueva N; Gómez-Román J; Hidalgo M; López-Ríos F PLoS One; 2014; 9(9):e107200. PubMed ID: 25248157 [TBL] [Abstract][Full Text] [Related]
7. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802 [TBL] [Abstract][Full Text] [Related]
8. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132 [TBL] [Abstract][Full Text] [Related]
9. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC). Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969 [TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of immunohistochemistry and fluorescent Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679 [TBL] [Abstract][Full Text] [Related]
11. New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC-in situ hybridization assay. Nitta H; Tsuta K; Yoshida A; Ho SN; Kelly BD; Murata LB; Kosmeder J; White K; Ehser S; Towne P; Schemp C; McElhinny A; Ranger-Moore J; Bieniarz C; Singh S; Tsuda H; Grogan TM J Thorac Oncol; 2013 Aug; 8(8):1019-31. PubMed ID: 23817194 [TBL] [Abstract][Full Text] [Related]
12. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study. Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850 [TBL] [Abstract][Full Text] [Related]
13. A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. Le Quesne J; Maurya M; Yancheva SG; O'Brien M; Popat S; Wotherspoon AC; de Castro DG; Nicholson AG J Thorac Oncol; 2014 Jun; 9(6):769-74. PubMed ID: 24787965 [TBL] [Abstract][Full Text] [Related]
14. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens]. Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study. Bironzo P; Melocchi L; Monica V; Trebeschi D; Barbieri F; Maiello E; Migliorino MR; Lombardi A; Tiseo M; Righi L; Graziano P; Rossi G; Novello S Pathologica; 2022 Aug; 114(4):278-287. PubMed ID: 36083243 [TBL] [Abstract][Full Text] [Related]
16. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200 [TBL] [Abstract][Full Text] [Related]
17. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079 [TBL] [Abstract][Full Text] [Related]
18. For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody. Taheri D; Zahavi DJ; Del Carmen Rodriguez M; Meliti A; Rezaee N; Yonescu R; Ricardo BF; Dolatkhah S; Ning Y; Bishop JA; Netto GJ; Sharma R Virchows Arch; 2016 Sep; 469(3):345-50. PubMed ID: 27271275 [TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples. Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958 [TBL] [Abstract][Full Text] [Related]
20. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma. Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]